PCDH17 and acute myeloid leukemia: Moreover, PCDH17 status identified a poor-prognostic subset of patients within the FLT3-ITDnegative/NPM1mutated low-risk CN-AML group (P = 0.011, Fig. 6d), although this analysis is limited by a relatively small number of patients (n = 31).